Am J Transplant, Volume 17, Suppl 3 Archives - Page 173 of 181 - ATC Abstracts

2017 American Transplant Congress
Prolonged Survival with Co-Stimulatory Blockade Based Immunosuppression in Pig-to-Primate Liver Xenotransplantation.
J. Shah, M. Patel, N. Elias, I. Rosales, N. Navarro-Alvarez, M. Hertl, A. Cosimi, R. Colvin, J. Markmann, D. Sachs, P. Vagefi.
Massachusetts General Hospital, Boston, MA
Background: Since the first attempt in 1968, survival following pig-to-baboon liver xenotransplantation (LXT) has been limited to <9-days due to a lethal coagulopathy. To improve…
2017 American Transplant Congress
Higher Mortality Among Candidates Who Refused Increased-Infectious Risk Kidney Offers.
M. Bowring, L. Kucirka, A. Massie, C. Holscher, D. Segev.
JHU, Baltimore
Increased infectious risk donors (IRD) are younger and healthier than most deceased donors, but IRD kidneys are discarded at higher rates despite potential benefit to…
2017 American Transplant Congress
The New Kidney Allocation System in France Meets it's Targets: Improving Age and HLA DR-QD Matching for Young Adults.
C. Jacquelinet, B. Audry, F. Bayer, M. Macher.
Direction Medicale et Scientifique, Agence de la Biomedecine, Saint-Denis, France
A new KAS was implemented in France as of February 2015, resulting from an intensive 3 yrs-simulation work in interaction with KTx advisory committee and…
2017 American Transplant Congress
Long-Term Outcomes After Liver Transplantation (tx) with Everolimus (EVR) and Mycophenolic Acid (MPA) in a Calcineurin Inhibitor-Free Regimen: The CERTITUDE Trial.
F. Saliba,¹ C. Duvoux,² S. Dharancy,³ J. Dumortier,⁴ Y. Calmus,⁵ F. Di Giambattista,⁶ F. Conti.⁵
¹AP-HP Hôpital Paul Brousse, Villejuif, France; ²AP-HP Hôpital Henri Mondor, Créteil, France; ³CHRU de Lille, Lille, France; ⁴Hôpital Edouard Herriot, Lyon, France; ⁵AP-HP Hôpital Pitié Salpêtrière, Paris, France; ⁶Novartis Pharma SAS, Rueil-Malmaison, France
Background. Long-term outcomes under EVR with MPA and no calcineurin inhibitor are undocumented after liver tx.Methods. CERTITUDE is a prospective, multicenter, observational study of liver…
2017 American Transplant Congress
A Novel Belatacept Regimen to Optimize Efficacy and Safety.
D. Wojciechowski,¹ S. Chandran,² M. Sarwal,² J. Yang,² F. Vincenti.²
¹MGH, Boston; ²UCSF, San Francisco
Despite superior long term graft survival when compared to cyclosporine, the use of the FDA approved belatacept regimen in clinical practice has been constrained by…
2017 American Transplant Congress
Rituximab Desensitization (DES) and Alemtuzumab Induction Significantly Reduced EBV Viremia and Post-Transplant Lymphoproliferative Disorder (PTLD) in HLA-Sensitized (HS) Kidney Transplant Patients.
B.-H. Shin,¹ S. Ge,¹ J. Mirocha,² D. Thomas,¹ E. Rodriguez,¹ C. Chao,¹ O. Galera,¹ A. Vo,¹ J. Choi,¹ A. Peng,¹ J. Kahwaji,¹ S. Jordan,¹ M. Toyoda.¹
¹Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Biostatistics Core, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA
Background: PTLD is a serious complication in KTx pts and is usually associated with EBV infection. Recent studies showed that rituximab treatment prior to Tx…
2017 American Transplant Congress
Inflammasome, Unfolded Protein Response, and T Cell Immunity in DAIH.
A. Arterbery,¹ M. Martinez,³ S. Lobritto,³ Y. Avitzur,² U. Ekong.¹
¹Ped Gastro. and Hep., Yale University, New Haven, CT; ²Gastro., Hep., and Nutr., Hospital for Sick Children, Toronto, ON, Canada; ³Ped. Gastro., Hep., and Nutr., Columbia University, New York, NY
Background: Regulatory T cells (Tregs) of patients with de novo autoimmune hepatitis (DAIH) secrete IL-17A & IFN-g; display TH1 & TH17 pehnotypes & are functionally…
2017 American Transplant Congress
Circulating Donor-Specific Memory B Cells (mBc) Discriminates Kidney Transplant Patients with Histological Lesions of ABMR in Absence of Circulating DSA.
S. Luque,² M. Lúcia,⁴ M. Jarque,² E. Crespo,² E. Melilli,¹ J. Martorell,³ J. Cruzado,^1,2 J. Torras,^1,2 J. Grinyó,^1,2 O. Bestard.^1,2
¹Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital, Barcelona, Catalunya, Spain; ²Experimental Nephrology Laboratory, IDIBELL, Barcelona, Catalunya, Spain; ³Immunogenetics Laboratory, Hospital Clínic, Barcelona, Catalunya, Spain; ⁴Transplant Immunology, School of Medicine, Stanford
Chronic (c)ABMR is a main cause of immune-mediated kidney allograft loss. For its diagnosis, specific histological lesions together with presence of circulating donor-specific alloantibodies (DSA)…
2017 American Transplant Congress
The Beneficial Effect of Janus Kinase 3 Inhibitor on Transplanted Islet via Protection from Oxidative Stress-Induced β Cell Death.
S.-J. Kang,^1,2,3,4 H. Chung,^1,2,3,4 S. Lee,^1,2,3,4 J.-S. Shin,^1,3,5 H.-J. Kim,^1,2,3,4 J.-M. Kim,^1,3,5 B.-H. Min,^1,3,5 S. Choi,^1,2,3,4 C.-G. Park.^1,2,3,4,5
¹Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea; ²Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; ³Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea; ⁴Department of Biomedical Sciences, Seoul National University, Seoul, Korea; ⁵Institute of Endemic Diseases, Seoul National University College of Medicine, Seoul, Korea
Janus kinase 3 (JAK3) is one of the molecules that make up the JAK-STAT signaling pathway that regulates numerous 40 cytokines. Thus, this cascade can…
2017 American Transplant Congress
The Impact of Belatacept on Anti-HLA Antibodies of Highly Sensitized Kidney Transplant Recipients.
R. Parsons, H. Decker, T. Pearson, C. Larsen, R. Bray, H. Gebel.
Emory Transplant Center, Atlanta, GA
Background: Anti-HLA antibodies often prevent successful organ transplantation. Interestingly, belatacept limits de novo antibody production within the germinal center, but its impact on long-lived plasma…